Brazil's Anvisa Approves First Human Trial of Nationally Developed Malaria Vaccine

Brazil's health regulator Anvisa has authorized a Phase 1 clinical trial for a domestically developed malaria vaccine, to be tested on 48 healthy volunteers with no prior infection. The vaccine uses 100% national technology, marking a significant step in Brazil's biomedical self-sufficiency. The trial's early stage and small sample size mean efficacy remains unproven, but approval signals progress in malaria prevention research.